Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy - The Pharmacogenomics Journal
Nature
Last updated: April 24, 2026
This study is the first to investigate an international professional body's role in assessing cardiovascular prescribers' access to pharmacogenomic (PGx) testing. It focuses on the availability of PGx testing, clinical decision support, patient information, and personalized medicine resources for cardiovascular prescribers.
- Key Findings: Access to PGx testing for cardiovascular prescribers varies significantly, with limited availability in many regions.
- Clinical decision support tools incorporating PGx information are emerging but not yet widely integrated into clinical practice.
- Patient-focused information regarding PGx in cardiovascular care is generally scarce.
- There is a recognized need for enhanced education and resources to facilitate the adoption of PGx in cardiovascular medicine.
- International collaboration and professional bodies are crucial for standardizing and promoting PGx implementation.
- Barriers to adoption include cost, lack of awareness, and limited infrastructure for widespread PGx testing.
- The study highlights the potential of PGx to personalize cardiovascular treatment and improve patient outcomes.
- Further research and policy development are recommended to address existing gaps in access and utilization.
